401 related articles for article (PubMed ID: 27462398)
1. ActRII blockade protects mice from cancer cachexia and prolongs survival in the presence of anti-cancer treatments.
Hatakeyama S; Summermatter S; Jourdain M; Melly S; Minetti GC; Lach-Trifilieff E
Skelet Muscle; 2016; 6():26. PubMed ID: 27462398
[TBL] [Abstract][Full Text] [Related]
2. Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism.
Nunn E; Jaiswal N; Gavin M; Uehara K; Stefkovich M; Drareni K; Calhoun R; Lee M; Holman CD; Baur JA; Seale P; Titchenell PM
Mol Metab; 2024 Feb; 80():101880. PubMed ID: 38218536
[TBL] [Abstract][Full Text] [Related]
3. Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy.
Morvan F; Rondeau JM; Zou C; Minetti G; Scheufler C; Scharenberg M; Jacobi C; Brebbia P; Ritter V; Toussaint G; Koelbing C; Leber X; Schilb A; Witte F; Lehmann S; Koch E; Geisse S; Glass DJ; Lach-Trifilieff E
Proc Natl Acad Sci U S A; 2017 Nov; 114(47):12448-12453. PubMed ID: 29109273
[TBL] [Abstract][Full Text] [Related]
4. An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy.
Lach-Trifilieff E; Minetti GC; Sheppard K; Ibebunjo C; Feige JN; Hartmann S; Brachat S; Rivet H; Koelbing C; Morvan F; Hatakeyama S; Glass DJ
Mol Cell Biol; 2014 Feb; 34(4):606-18. PubMed ID: 24298022
[TBL] [Abstract][Full Text] [Related]
5. Prevention of cachexia-like syndrome development and reduction of tumor progression in inhibin-deficient mice following administration of a chimeric activin receptor type II-murine Fc protein.
Li Q; Kumar R; Underwood K; O'Connor AE; Loveland KL; Seehra JS; Matzuk MM
Mol Hum Reprod; 2007 Sep; 13(9):675-83. PubMed ID: 17704537
[TBL] [Abstract][Full Text] [Related]
6. Complete reversal of muscle wasting in experimental cancer cachexia: Additive effects of activin type II receptor inhibition and β-2 agonist.
Toledo M; Busquets S; Penna F; Zhou X; Marmonti E; Betancourt A; Massa D; López-Soriano FJ; Han HQ; Argilés JM
Int J Cancer; 2016 Apr; 138(8):2021-9. PubMed ID: 26595367
[TBL] [Abstract][Full Text] [Related]
7. Muscle and serum metabolomes are dysregulated in colon-26 tumor-bearing mice despite amelioration of cachexia with activin receptor type 2B ligand blockade.
Lautaoja JH; Lalowski M; Nissinen TA; Hentilä J; Shi Y; Ritvos O; Cheng S; Hulmi JJ
Am J Physiol Endocrinol Metab; 2019 May; 316(5):E852-E865. PubMed ID: 30860875
[TBL] [Abstract][Full Text] [Related]
8. Treating cachexia using soluble ACVR2B improves survival, alters mTOR localization, and attenuates liver and spleen responses.
Nissinen TA; Hentilä J; Penna F; Lampinen A; Lautaoja JH; Fachada V; Holopainen T; Ritvos O; Kivelä R; Hulmi JJ
J Cachexia Sarcopenia Muscle; 2018 Jun; 9(3):514-529. PubMed ID: 29722201
[TBL] [Abstract][Full Text] [Related]
9. Aerobic and resistance training dependent skeletal muscle plasticity in the colon-26 murine model of cancer cachexia.
Khamoui AV; Park BS; Kim DH; Yeh MC; Oh SL; Elam ML; Jo E; Arjmandi BH; Salazar G; Grant SC; Contreras RJ; Lee WJ; Kim JS
Metabolism; 2016 May; 65(5):685-698. PubMed ID: 27085776
[TBL] [Abstract][Full Text] [Related]
10. Effects of bimagrumab, an activin receptor type II inhibitor, on pituitary neurohormonal axes.
Garito T; Zakaria M; Papanicolaou DA; Li Y; Pinot P; Petricoul O; Laurent D; Rooks D; Rondon JC; Roubenoff R
Clin Endocrinol (Oxf); 2018 Jun; 88(6):908-919. PubMed ID: 29566437
[TBL] [Abstract][Full Text] [Related]
11. Prevention of chemotherapy-induced cachexia by ACVR2B ligand blocking has different effects on heart and skeletal muscle.
Hulmi JJ; Nissinen TA; Räsänen M; Degerman J; Lautaoja JH; Hemanthakumar KA; Backman JT; Ritvos O; Silvennoinen M; Kivelä R
J Cachexia Sarcopenia Muscle; 2018 Apr; 9(2):417-432. PubMed ID: 29230965
[TBL] [Abstract][Full Text] [Related]
12. Targeting the Activin Receptor Signaling to Counteract the Multi-Systemic Complications of Cancer and Its Treatments.
Hulmi JJ; Nissinen TA; Penna F; Bonetto A
Cells; 2021 Feb; 10(3):. PubMed ID: 33671024
[TBL] [Abstract][Full Text] [Related]
13. The systemic activin response to pancreatic cancer: implications for effective cancer cachexia therapy.
Zhong X; Pons M; Poirier C; Jiang Y; Liu J; Sandusky GE; Shahda S; Nakeeb A; Schmidt CM; House MG; Ceppa EP; Zyromski NJ; Liu Y; Jiang G; Couch ME; Koniaris LG; Zimmers TA
J Cachexia Sarcopenia Muscle; 2019 Oct; 10(5):1083-1101. PubMed ID: 31286691
[TBL] [Abstract][Full Text] [Related]
14. Selumetinib Attenuates Skeletal Muscle Wasting in Murine Cachexia Model through ERK Inhibition and AKT Activation.
Quan-Jun Y; Yan H; Yong-Long H; Li-Li W; Jie L; Jin-Lu H; Jin L; Peng-Guo C; Run G; Cheng G
Mol Cancer Ther; 2017 Feb; 16(2):334-343. PubMed ID: 27599525
[TBL] [Abstract][Full Text] [Related]
15. Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia.
Benny Klimek ME; Aydogdu T; Link MJ; Pons M; Koniaris LG; Zimmers TA
Biochem Biophys Res Commun; 2010 Jan; 391(3):1548-54. PubMed ID: 20036643
[TBL] [Abstract][Full Text] [Related]
16. Antioxidant supplementation accelerates cachexia development by promoting tumor growth in C26 tumor-bearing mice.
Assi M; Derbré F; Lefeuvre-Orfila L; Rébillard A
Free Radic Biol Med; 2016 Feb; 91():204-14. PubMed ID: 26708754
[TBL] [Abstract][Full Text] [Related]
17. Combined administration of fucoidan ameliorates tumor and chemotherapy-induced skeletal muscle atrophy in bladder cancer-bearing mice.
Chen MC; Hsu WL; Hwang PA; Chen YL; Chou TC
Oncotarget; 2016 Aug; 7(32):51608-51618. PubMed ID: 27323407
[TBL] [Abstract][Full Text] [Related]
18. Modified Sijunzi decoction can alleviate cisplatin-induced toxicity and prolong the survival time of cachectic mice by recovering muscle atrophy.
Chen JM; Yang TT; Cheng TS; Hsiao TF; Chang PM; Leu JY; Wang FS; Hsu SL; Huang CF; Lai JM
J Ethnopharmacol; 2019 Apr; 233():47-55. PubMed ID: 30590199
[TBL] [Abstract][Full Text] [Related]
19. Capecitabine improves cancer cachexia and normalizes IL-6 and PTHrP levels in mouse cancer cachexia models.
Fujimoto-Ouchi K; Onuma E; Shirane M; Mori K; Tanaka Y
Cancer Chemother Pharmacol; 2007 May; 59(6):807-15. PubMed ID: 17009035
[TBL] [Abstract][Full Text] [Related]
20. Prevention of cancer cachexia by pyrrolidine dithiocarbamate (PDTC) in colon 26 tumor-bearing mice.
Nai YJ; Jiang ZW; Wang ZM; Li N; Li JS
JPEN J Parenter Enteral Nutr; 2007; 31(1):18-25. PubMed ID: 17202436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
